Suppr超能文献

高渗盐水用于囊性纤维化患者的黏液清除与肺功能研究

Mucus clearance and lung function in cystic fibrosis with hypertonic saline.

作者信息

Donaldson Scott H, Bennett William D, Zeman Kirby L, Knowles Michael R, Tarran Robert, Boucher Richard C

机构信息

University of North Carolina at Chapel Hill Cystic Fibrosis Research and Treatment Center, Chapel Hill 27599, USA.

出版信息

N Engl J Med. 2006 Jan 19;354(3):241-50. doi: 10.1056/NEJMoa043891.

Abstract

BACKGROUND

Abnormal homeostasis of the volume of airway surface liquid in patients with cystic fibrosis is thought to produce defects in mucus clearance and airway defense. Through osmotic forces, hypertonic saline may increase the volume of airway surface liquid, restore mucus clearance, and improve lung function.

METHODS

A total of 24 patients with cystic fibrosis were randomly assigned to receive treatment with inhaled hypertonic saline (5 ml of 7 percent sodium chloride) four times daily with or without pretreatment with amiloride. Mucus clearance and lung function were measured during 14-day baseline and treatment periods.

RESULTS

Long-term inhalation of hypertonic saline without pretreatment with amiloride (i.e., with placebo pretreatment) resulted in a sustained (> or =8 hours) increase in 1-hour rates of mucus clearance, as compared with those with amiloride pretreatment (14.0+/-2.0 vs. 7.0+/-1.5 percent, respectively; P=0.02) and increased 24-hour rates of mucus clearance over baseline. Furthermore, inhalation of hypertonic saline with placebo improved the forced expiratory volume in one second (FEV1) between the baseline period and the treatment period (mean difference, 6.62 percent; 95 percent confidence interval, 1.6 to 11.7; P=0.02), whereas hypertonic saline with amiloride did not improve FEV1 (mean difference, 2.9 percent; 95 percent confidence interval, -2.2 to 8.0; P=0.23). Forced vital capacity (FVC), the forced expiratory flow between 25 and 75 percent of FVC (FEF25-75), and respiratory symptoms also significantly improved in patients treated with hypertonic saline and placebo, whereas the residual volume as a proportion of total lung capacity (RV:TLC) did not change in either group. A comparison of the changes in lung function in the two groups showed no significant difference. In vitro data suggested that sustained hydration of airway surfaces was responsible for the sustained improvement in mucus clearance, whereas inhibition of osmotically driven water transport by amiloride accounted for the observed loss of clinical benefit.

CONCLUSIONS

In patients with cystic fibrosis, inhalation of hypertonic saline produced a sustained acceleration of mucus clearance and improved lung function. This treatment may protect the lung from insults that reduce mucus clearance and produce lung disease.

摘要

背景

囊性纤维化患者气道表面液体量的内稳态异常被认为会导致黏液清除和气道防御功能缺陷。通过渗透力,高渗盐水可能会增加气道表面液体量,恢复黏液清除功能,并改善肺功能。

方法

总共24例囊性纤维化患者被随机分配,接受每日4次吸入高渗盐水(5毫升7%氯化钠)的治疗,其中部分患者在治疗前使用或不使用氨氯吡咪预处理。在为期14天的基线期和治疗期内测量黏液清除功能和肺功能。

结果

与使用氨氯吡咪预处理的患者相比,长期吸入高渗盐水且未使用氨氯吡咪预处理(即使用安慰剂预处理)的患者,其1小时黏液清除率持续(≥8小时)增加(分别为14.0±2.0%和7.0±1.5%;P=0.02),且24小时黏液清除率较基线期有所提高。此外,使用安慰剂吸入高渗盐水可改善基线期和治疗期之间的一秒用力呼气量(FEV1)(平均差异为6.62%;95%置信区间为1.6至11.7;P=0.02),而使用氨氯吡咪的高渗盐水组未改善FEV1(平均差异为2.9%;95%置信区间为-2.2至8.0;P=0.23)。使用高渗盐水和安慰剂治疗的患者,用力肺活量(FVC)、FVC的25%至75%之间的用力呼气流量(FEF25-75)以及呼吸道症状也有显著改善,而两组患者的残气量占肺总量的比例(RV:TLC)均未改变。两组肺功能变化的比较显示无显著差异。体外数据表明,气道表面的持续水化作用是黏液清除功能持续改善的原因,而氨氯吡咪对渗透驱动的水转运的抑制作用则解释了观察到的临床益处丧失的原因。

结论

在囊性纤维化患者中,吸入高渗盐水可使黏液清除功能持续加速并改善肺功能。这种治疗方法可能保护肺部免受降低黏液清除功能并导致肺部疾病的损伤。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验